Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90434 | 0.84 | ROCK2 (0.38) | KDM4EALDH1A1HPGD | |
| SCHEMBL89853 | 0.80 | CYP2C9 (0.39) | ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL8236634 | 0.80 | ALDH1A1 (0.34) | IRAK4KDM4EALDH1A1HPGD | |
| SCHEMBL12526702 | 0.78 | AR (0.38) | ARKDM4EIKBKETBK1 | |
| SCHEMBL89959 | 0.77 | ULK1 (0.44) | AR | |
| SCHEMBL89459 | 0.76 | LMNA (0.40) | KDM4EALDH1A1 | |
| SCHEMBL88797 | 0.75 | AR (0.45) | ARKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL89415 | 0.74 | EGFR (0.41) | ARKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL25039605 | 0.73 | HTT (0.39) | KDM4EALDH1A1 | |
| SCHEMBL8265618 | 0.73 | L3MBTL1 (0.42) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | IRAK4 1627/4885AR 1411/4885KDM4E 1650/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | IRAK4 1690/4885AR 2440/4885KDM4E 1140/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | IRAK4 1423/4885AR 3040/4885KDM4E 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.